BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9316670)

  • 1. Clinical usefulness of apomorphine in movement disorders.
    Colosimo C; Merello M; Albanese A
    Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
    Sharma JC; Macnamara L; Hasoon M; Vassallo M
    Int J Clin Pract; 2004 Nov; 58(11):1028-32. PubMed ID: 15605666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Hauser RA; LeWitt PA; Comella CL
    Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apomorphine].
    Esteban Muñoz J
    Neurologia; 1995 Oct; 10(8):330-7. PubMed ID: 8554783
    [No Abstract]   [Full Text] [Related]  

  • 18. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
    Jenner P; Katzenschlager R
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.